EMTT in Musculoskeletal Disorders: Selected Clinical and Experimental Studies
Extracorporeal Magnetotransduction Therapy (EMTT) is a non-invasive treatment modality increasingly used in orthopaedics, sports medicine and pain management. As interest grows in electromagnetic approaches for chronic pain and musculoskeletal regeneration, a review of the current clinical and experimental literature is warranted.
The following overview summarises published data by indication and highlights key findings from randomised controlled trials (RCTs), prospective studies and laboratory research.1–8
Clinical Evidence by Indication
Degenerative Spinal and Joint Pain
A single-centre, randomised, placebo-controlled trial conducted in Germany evaluated EMTT in patients with knee osteoarthritis, rotator cuff enthesopathy and lumbar spondyloarthrosis (N = 126).1 Participants received eight EMTT treatments or eight sham treatments at weekly intervals. The primary outcome was quality of life, assessed using the SF-12 Physical and Mental Component Summary scales (PCS and MCS), while pain intensity was evaluated as a secondary outcome using the Visual Analogue Scale (VAS, 0–10).
Compared with placebo, the EMTT group demonstrated greater improvements in SF-12 PCS and stronger pain reduction at 6 and 12 weeks.1 These findings suggest a potential role for EMTT in degenerative musculoskeletal disorders characterised by chronic pain and functional limitation.
In a prospective randomised controlled trial involving patients with chronic non-specific low back pain (N = 44 per group; 87 patients analysed), conventional non-invasive treatment consisting of physiotherapy and analgesic medication was compared with the same treatment supplemented by EMTT over a six-week period.2 The study reported greater improvements in pain and functional outcomes in the group receiving additional EMTT. As the study did not include a sham intervention, non-specific treatment effects cannot be excluded.
Shoulder Enthesopathies
A further randomised, placebo-controlled trial investigated EMTT in shoulder joint enthesopathies (N = 43).3 Patients had clinically relevant shoulder pain due to degenerative tendinopathies that had not responded to conservative non-invasive treatments.
Over a 12-week observation period, VAS pain scores decreased more markedly in the EMTT group than in the placebo group, accompanied by improvements in in the physical component of the SF-12 (PCS). No clinically relevant adverse events were reported.3
These findings contribute to the growing evidence base for EMTT in chronic enthesopathies and degenerative tendon-related shoulder disorders.
Sports-Related Tendinopathies and Osteitis Pubis
Additional prospective clinical studies provide further insight into EMTT in sports-related musculoskeletal disorders.
In athletes with chronic Achilles tendinopathy, EMTT was associated with reductions in activity-related pain and improvements in validated tendon function scores following a structured treatment course.4
Similarly, in a prospective series of athletes with chronic aseptic osteitis pubis, EMTT was linked to decreased pain and return to sport in cases where established conservative therapy had not yielded sufficient improvement.5
While these studies are limited by sample size and non-placebo-controlled study design, they suggest that EMTT may represent a non-invasive adjunct option in high-demand sports settings.
Biological Rationale – Insights from Laboratory Research
Experimental studies provide insights into cellular responses to EMTT under laboratory conditions.
In vitro exposure of human bone marrow-derived mesenchymal stem cells to EMTT increased angiogenic mediators such as vascular endothelial growth factor (VEGF) and upregulated osteogenic differentiation markers.6 These findings indicate potential stimulation of vascular signalling pathways and maturation of bone-forming cells.
Further experimental investigations demonstrated enhanced osteoblast activity and mineralisation processes under EMTT stimulation, suggesting modulation of bone-related cellular processes in vitro.7
A separate in vitro study identified changes in human tenocytes associated with cellular senescence and extracellular matrix remodelling.8
Key Points for Clinical Practice
- EMTT has been evaluated in prospective clinical trials addressing degenerative joint disease, enthesopathies and chronic non-specific low back pain, including randomised controlled studies with up to N = 126 participants.1–3
- In a sham-controlled trial, EMTT was associated with greater reductions in pain (VAS) and improvements in physical function (SF-12 PCS) compared with sham treatment over a follow-up period of up to 12 weeks.1 A smaller randomised study in chronic non-specific low back pain reported greater improvements in pain and functional outcomes when EMTT was added to conventional therapy.2
- Uncontrolled prospective studies in sports-related indications reported reductions in pain and improvements in functional or return-to-sport outcomes following EMTT treatment, providing supportive clinical observations that warrant further investigation in controlled trials.4,5
- Across clinical investigations, EMTT was reported to be well tolerated; adverse effects were predominantly mild and transient, such as temporary local pain or skin redness.1–3
- Experimental studies have reported cellular responses related to angiogenic and osteogenic processes under EMTT exposure.6,7 In addition, changes were observed in human tenocytes affecting processes of cellular senescence and extracellular matrix remodelling.8 Further studies are required before these findings can be translated to humans.
Conclusion: Positioning EMTT in Evidence-Based Musculoskeletal Care
Taken together, the current literature suggests that Extracorporeal Magnetotransduction Therapy may represent a promising non-invasive adjunct within multimodal treatment concepts for selected patients with chronic degenerative musculoskeletal disorders and persistent pain.
This overview is intended for healthcare professionals and summarises published literature. Clinical decision-making should be based on individual patient assessment, regulatory approval status and current clinical guidelines.
References
1. Hollander, K., et al. (2026). Extracorporeal magnetotransduction therapy (EMTT) for management of musculoskeletal disorders: A double-blind, placebo-controlled, randomised trial. Journal of Back and Musculoskeletal Rehabilitation, 39(3), 885-895. https://doi.org/10.1177/10538127251400083
2. Krath, A., et al. (2017). Electromagnetic transduction therapy in non-specific low back pain: A prospective randomised controlled trial. Journal of Orthopaedics, 14(3), 410-415. https://doi.org/10.1016/j.jor.2017.06.016
3. Gerdesmeyer, L., et al. (2023). Prospective double blinded placebo controlled trial of high energetic magneto transduction therapy in shoulder joint enthesiopathies. Sports Orthopaedics and Traumatology, 39(2), 212. https://doi.org/10.1016/j.orthtr.2023.03.045
4. Gerdesmeyer, L., et al. (2017) Electromagnetic Transduction Therapy for Achilles Tendinopathy: A Preliminary Report on a New Technology. The Journal of Foot and Ankle Surgery, 56(5), 964-967. https://doi.org/10.1053/j.jfas.2017.06.014
5. Klüter, T., et al. (2018) Electromagnetic Transduction Therapy in Patients with Chronic Aseptic Osteitis Pubis. Journal of Orthopedic Research and Therapy, 3(12), 1113. DOI: 10.29011/2575-8241.001113
6. Gerdesmeyer, L., et al. (2022) Stimulation of human bone marrow mesenchymal stem cells by electromagnetic transduction therapy – EMTT. Electromagnetic Biology and Medicine, 41(3), 304-314. https://doi.org/10.1080/15368378.2022.2079672
7. Gerdesmeyer, L., et al. (2024) Extracorporeal Magnetotransduction Therapy as a New Form of Electromagnetic Wave Therapy: From Gene Upregulation to Accelerated Matrix Mineralization in Bone Healing. Biomedicines, 12(10), 2269. https://doi.org/10.3390/biomedicines12102269
8. Mancini, M., et al. (2025) Electromagnetic Transduction Therapy (EMTT) Enhances Tenocyte Regenerative Potential: Evidence for Senolytic-like Effects and Matrix Remodeling. International Journal of Molecular Sciences, 26(15), 7122. https://doi.org/10.3390/ijms26157122
